Navigate trial complexity and ensure rigorous clinical safety with an experienced benign hematology CRO
At Parexel, we combine deep therapeutic expertise in benign hematology with highly coordinated operational execution to support you in executing your clinical trials and accelerate the path of your investigational product to market, ultimately helping change patient lives for the better. Our hematology team works closely with clinical operations to manage the complexities of these trials, with:
- Specialized site coordination
- Laboratory standardization
- Rigorous medical monitoring
- Patient recruitment and engagement that reflect patients’ lived experiences
As a proven benign hematology CRO, we’ll give you access to the right investigators and the right patients through our longstanding relationships with key opinion leaders, treatment centers, and patient advocacy organizations. Our Site Alliance network accelerates site activation and supports global enrollment even in the most challenging conditions.
Experience in the past 5 years with non-malignant hematology
+
clinical projects
+
enrolled patients
+
sites
Sickle cell disease
We help you navigate the unique challenges of sickle cell disease (SCD) by combining our SCD experience with a global network of specialized sites. Our advanced regulatory, statistical, and medical expertise enables us to design adaptive trials, develop validated endpoints, and implement robust safety monitoring for complex SCD populations. By engaging with patient communities and advocacy groups, we also improve recruitment and retention while reducing patient burden.
Hemophilia
Hemophilia trials are associated with various hurdles. Patient populations are extremely heterogeneous across various phenotypes. Bleeding outcomes are difficult to measure accurately since they are variable and subjective in nature. Safety monitoring is critical for potential adverse events such as thrombosis.
We overcome these challenges with our extensive experience in rare bleeding disorders and a strong track record in benign hematology drug development. By working with us, you’ll have access to our hemophilia treatment centers and specialized coagulation laboratories around the world, with extensive experience in hemophilia-specific clinical management. Parexel is also able to tap into our ability to design innovative endpoints that capture clinically meaningful outcomes, implement robust medical monitoring strategies, and adapt to the latest regulatory guidance in order to best support your study.
Bone marrow failure diseases
Bone marrow failure diseases are widely heterogenous, progress in diverse ways, and respond unpredictably to treatment across patient populations. These diseases are associated with significant morbidity for patients and require careful safety monitoring and site selection during clinical trials.
As your benign hematology CRO, we’re ready to deliver these trials with speed, precision, and care. We help you design clinically meaningful endpoints for heterogeneous populations, implement robust medical monitoring strategies, and navigate regulatory pathways. We also accommodate disease variability with adaptive trial designs and use patient registries and real-world data to improve recruitment and contextualize trial findings.
Neutropenia
From protocol to regulatory submission, we’re a comprehensive partner for all benign hematology drug development, including investigational products that target neutropenic diseases. Our deep expertise and global network of specialized oncology and hematology centers help us meet each trial’s unique needs. We mitigate the risk of infection with clear guidance outlined within the protocol, robust medical monitoring, lean into adaptive trial designs to manage disease variability, and navigate evolving regulatory guidance with specialized medical oversight.